TQH3821
/ Sino Biopharm
- LARVOL DELTA
Home
Next
Prev
1 to 6
Of
6
Go to page
1
February 20, 2025
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=195 | Terminated | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Jan 2025; Per sponsor request.
Trial primary completion date • Trial termination • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
January 22, 2024
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
(clinicaltrials.gov)
- P1 | N=63 | Completed | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Dec 2023 ➔ May 2023
Trial completion • Trial completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
September 06, 2023
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=204 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting
Enrollment open • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
August 16, 2023
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=204 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Jul 2023 ➔ Oct 2023
Trial initiation date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
May 09, 2023
A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis
(clinicaltrials.gov)
- P2 | N=204 | Not yet recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
May 19, 2022
A Clinical Trial of Safety and Tolerance of TQH3821 Tablets in Adult Healthy Subjects
(clinicaltrials.gov)
- P1 | N=62 | Recruiting | Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P1 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CRP
1 to 6
Of
6
Go to page
1